Company news

Share this article:
Schering-Plough ended its partnership with Novacea after its prostate cancer compound Asentar failed in clinical trials. The companies ended a late-stage study of the drug late last year citing an "imbalance" of deaths. Patients taking Asentar died more often than those taking a standard treatment. Asentar rights will be returned to Novacea. Despite the higher-than-expected number of deaths, the company said in published reports it still believes Asentar is a safe drug and called Schering-Plough's decision unexpected.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.